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Introduction
Each year many scientific meetings are held on stem cells to
appraise the state of knowledge on their potency, differentiation
and applications. So why did we hold another meeting? Because
we thought one aspect was not adequately addressed in the
others. When thinking of how our body is derived from a single
fertilized egg, it is self-evident that the embryo is the ‘mother’ of all
stem cells. This fact is probably overlooked because it is so
remote (decades back in our lives!) and because embryonic stem
cells do not exist as such in the embryo. However, this also tends
to be ignored on purpose in many stem cell meetings because
working on (human) embryos brings up substantial ethical con-
cerns that bear on the scientific undertaking like nothing else. The
origin of stem cells has become even more of a sensitive issue
since the discovery in 2006 that embryonic stem (ES) cell-like
cells can be generated in a Petri dish straight from somatic cells
by retrovirus-mediated transfer of selected genes. These new
cells have been named ‘induced pluripotent stem’ (iPS) cells and
have been obtained without any egg or embryo consumption
(Takahashi and Yamanaka, 2006). This leads to the first topic of
our meeting: natural and induced pluripotency. Many stem cells,
irrespective of their origin (adult, fetal, embryonic, induced),
almost invariably grow in vitro as multicellular structures referred
to as ‘colonies’ to secure their potency. From an ontogenic
perspective, the first ‘colony’ is arguably the morula-stage embryo
with its 8-16 cells. Despite the fact that access to embryos is
inherently difficult, more about cell fate control appears to be
known in embryos than in stem cells. This leads to the second
topic of our meeting: mechanisms of cell fate control. Stem cells
can be propagated for many cell doublings and can give rise to a
wide range of cell types found in the body. This makes them
excellent candidates for cell- and tissue-replacement therapies.
However, there is a general sense that the more potent stem cells
are, the more likely they are to deviate from the normal physiologi-
cal path of their differentiation, and that they may give rise to
tumours. This leads to the third and last topic of our meeting: adult
and cancer stem cells.
The Pavia meeting took place on January 17th and 18th 2008





Collegio Borromeo, two University colleges in Pavia, with a
tradition of excellence with roots in the Renaissance. A small but
prominent group of scientists lectured at this meeting – in alpha-
betical order: James Adjaye (Germany), Anne Grete Byskov
(Denmark), Jose Cibelli (USA), Ruggero De Maria (Italy), Stephen
Minger (UK), Maurilio Sampaolesi (Belgium), Hans Schöler (Ger-
many), Giuseppe Testa (Italy), Catherine Verfaillie (Belgium) and
Magdalena Zernicka-Goetz (UK). All the speakers were invited to
contribute to this report.
Natural and induced pluripotency
Stem cells are indispensable to the organism as they safe-
guard tissue homeostasis through a fine balance of self-renewal
and differentiation. Stem cells occur in very small numbers in adult
tissues and in higher numbers in the fetus and its annexes. Thus,
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they can be derived from whole embryos or parts thereof. There
is probably no sounder example of self-renewal and differentia-
tion than the properties of ES cells. These cells, first derived from
mouse embryos (Martin, 1981; Evans and Kaufman, 1981) and
later obtained in humans (Thomson et al., 1998), can give rise to
all the tissue types of the adult body, as was conclusively
demonstrated in mice (Nagy et al., 1993). The prevalent definition
of mouse ES cells as pluripotent underscores their ability to form
all tissues except the trophectoderm (TE) after culture under
current protocols. In analogy, human ES cells (hESCs) are also
considered pluripotent.
Over the last decade, increasing enthusiasm, as well as
ethical concerns about the potential of hESCs for therapeutic
uses, have divided the public opinion. On the one hand, hES cells
may be differentiated into tissues that could be used in the
therapy of injured or diseased organs. On the other hand,
undifferentiated ES cells persisting in cell grafts have issued a
warning, as the undifferentiated cells typically cause tumours
(teratomas) in engrafted animals (Nussbaum et al., 2007; Shih et
al., 2007). However, sometimes the differentiated ES cells seemed
instead to be the cause of the tumours (Roy et al., 2006). Tumour
formation is enabled by a host of ES cell properties, including their
immunologic profile (Saric et al., 2008). Regardless of what ES
cells can or cannot do, the production of hES cells requires the
deployment of human embryos, which is held by many as unac-
ceptable because it prevents a potential human being from
coming into existence. In this respect, cloned embryos might be
less objectionable given their very limited ability for development
in utero.
Despite the complications inherent to hES cells, a large group
of scientists are still on this rocky road, not only to pursue clinical
prospects but also to gain knowledge on a model system that
holds important lessons on pluripotency. It is no news to these
scientists that the generation and maintenance of hES cells is
particularly laborious and tricky, thereby making the knowledge
harder to come by. In this light, it is remarkable that the first
laboratory to achieve iPS cells from human fibroblasts lacked a
published record of hESC work (Takahashi and Yamanaka,
2007). While this argues that anybody can handle hESCs, per-
haps it is more likely that the research went through a preliminary
phase of work, which has not been accounted. If so, the quest for
refined and standardized protocols for the derivation and mainte-
nance of hES cells remains on the agenda. In order to help
achieve these protocols, the International Stem Cell Initiative
(2007) has so far characterized 59 hESC lines from 17 laborato-
ries and 11 countries. Stephen Minger, a member of the Initiative,
explained at this meeting that there is a core set of features that
appear to be common to all the lines examined. These include the
expression of characteristic cell surface proteins, pluripotency
genes including Oct4, Nanog and Sox2 and the ability to differen-
tiate into cell types representative of all three germ layers.
However, certain differences are still unexplained. For example,
Minger displayed data indicating that individual hES cell lines
have different propensities to generate cells from each germ
layer, even when comparing hES cell lines generated in the same
laboratory under identical derivation and culture conditions (Pringle
and Minger, unpublished data). Anne Grete Byskov showed that
even within one colony of hESCs, there are regional differences
in the expression of defining markers (Laursen et al., 2007). This
observation emphasizes the fact that even ES cells derived from
one source are heterogeneous under current conditions. Byskov
then examined a property of ES cells that has been known in vivo
for a long time, but could not be reproduced in vitro until 2003: the
ability to form germ cells (Hübner et al., 2003). Consistent with this
ability, in sexually undifferentiated (female) gonads, Byskov de-
scribed a stem cell activity whereby oocytes appear to mature,
undergo parthenogenesis and produce a new generation of ‘stem
cells’ that again can differentiate into oocytes. Whether these
‘stem cells’ are primordial germ cells is under investigation. The
obvious remark is that altogether, based on the data of Minger and
Byskov, various factors contribute to the differences between and
within (human) ES cell lines. These factors include but are not
limited to differences among the precursors in the inner cell mass
(ICM) (Lauss et al., 2005; Furusawa et al., 2004), genetic back-
ground and culture conditions.
Typically hES cells are grown on feeder cells, either ‘xenogenic’
(e.g. mouse embryonic fibroblasts, MEFs) or ‘allogenic’ (human
somatic cells). James Adjaye showed that the ability of condi-
tioned media made from MEFs to support hESC self-renewal and
pluripotency depends primarily on one growth factor, FGF2. This
factor stimulates MEFs to secrete self-renewal supporting factors
(e.g. TGFβ1, GREM1 and INHBA), which in turn repress differen-
tiation-inducing activities such as BMP4 (Greber et al., 2007).
Adjaye also presented data on the complexity of the OCT4-
regulated transcriptional networks in stem cells based on ChIP-
on-chip, a technique that combines chromatin immunoprecipita-
tion (ChIP) with microarray technology (chip). From the presented
data it appears that there are distinct, evolutionarily conserved
(human to opossum) genetic modules containing OCT4-binding
motifs. For example, one of the highly conserved OCT4-binding
sites investigated so far is within the NANOG promoter, where
OCT4 forms a dimer with SOX2 thus facilitating binding to the
OCT4-SOX2-binding site. This arrangement is referred to as
‘module 1’. ‘Module 2’ consists of the OCT4-binding motif without
the SOX2-binding motif but contains either characterized or
uncharacterized motifs as deduced from the TRANSFAC data-
base of transcription factor binding sites (Jung, Lehrach and
Adjaye, unpublished). An example of a gene falling within ‘module
2’ is GADD45G. This gene is negatively regulated by OCT4 and
is implicated in a host of growth-regulatory mechanisms such as
DNA replication and repair, apoptosis, G2/M checkpoint control
and differentiation (Babaie et al., 2007).
Whether derived from a zygote or from a cloned embryo, ES
cells might not prove to be the ideal option for regenerative
medicine anyway, because of the highly controversial consump-
tion of potentially viable human embryos. Alternatives are being
pursued. For instance, Adjaye announced to our audience the first
achievement of iPS cells in Europe (Die Zeit, 17 Januar 2008) and
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presented initial results of his fibroblast reprogramming work
using defined factors (OCT4, SOX2, NANOG and LIN28). Be-
sides the new iPS approach, alternative approaches could be the
generation of hESCs by parthenogenesis and by interspecies
somatic cell nuclear transfer (iSCNT). These procedures are
currently being pursued by Jose Cibelli and his group (Behyan et
al., 2007). During parthenogenesis, an egg is ‘tricked’ by chemical
means to behave as if it had been fertilized (Cibelli et al., 2002).
This process has been shown to give rise to non-totipotent
embryos that are unable to develop into a full organism, while still
being able to give rise to ES cells (Allen et al., 1994). This partial
potency is in line with the definition of ES cells as pluripotent.
However, embryos generated by parthenogenesis can form TE –
the main exclusion criterion for totipotency. Alternatively, Cibelli
explained that a human somatic nucleus transplanted into a non-
human primate oocyte, activated by parthenogenesis, and cul-
tured to the blastocyst stage could generate immunotype-matched
human ES cells without consumption of any human oocytes or
embryos. Despite the potential benefits, iSCNT is a touchy issue
for regulatory authorities. Controversial results from human-to-
rabbit nuclear transfer experiments (Chen et al., 2003) suggest
that the final product is not a surrogate, but truly human. It came
therefore as a positive surprise that a short-term research license
for cross-species nuclear transfer was granted to Minger by the
UK’s Human Fertilization and Embryology Authority (HFEA),
while he was on his way to this meeting. The goal of this work is
to create cloned human embryonic stem cell lines from individuals
with known genetic mutations that result in a number of common
neurodegenerative conditions, including Alzheimer’s and
Parkinson’s diseases, as well as motor neuron disease and spinal
muscular atrophy (Minger, 2007).
Mechanisms of cell fate control
For a few years, ES cells have been derived outside of the
blastocyst stage. Indeed, ES cells have been derived from iso-
lated blastomeres of pre-blastocyst stage embryos (Klimanskaya
et al., 2007). This leads one to ask if early developmental stages
also have the heterogeneity that Minger and Byskov illustrated for
hESCs. Answering this question implies understanding whether
mammalian embryos have completely emancipated themselves
from the patterns and polarities that play such an important role
in the development of lower vertebrate taxa, e.g. Amphibia. It has
been clear since 1965 that “any rigid ‘pre-patterning’ must be
considered unlikely, at least in the mouse” (quote of Beatrice
Mintz by Anne McLaren, 1976). Despite this considered opinion,
which does not rule out developmental bias (in the sense that bias
is not the same as pre-patterning), the prevalent view of mamma-
lian development has been taken to the extreme of saying that
regulative processes make the blastomeres homogeneous. In-
deed, exposing bias in cell fate has been a challenge because the
regulative processes in the embryo would often mask its exist-
ence. Magdalena Zernicka-Goetz and her group have indeed
shown that early mouse blastomeres are not all alike in their
epigenetic nuclear makeup and are not equivalent in their devel-
opmental potential (Torres-Padilla et al., 2007). By tracking the
cleavage pattern, and thereby examining how the spatial
organisation of an early embryo is partitioned into individual cells
of the 4-cell stage embryo, her group was able to show that the
four blastomeres differ in the extent of histone H3 methylation at
Arginine 26 and undergo skewed allocation towards ICM or TE.
Deploying a very elegant set of micro-manipulation experiments,
Zernicka-Goetz and colleagues have further demonstrated that if
4-cell mouse embryos are reconstituted with blastomeres of the
same cleavage subtype, such chimaeras diverge in developmen-
tal outcomes (Piotrowska-Nitsche et al., 2005). Most recently, by
tracing all cells in embryos in 3D during the first 3 days of
development, Zernicka-Goetz’s group revealed that the skewed
allocation of individual blastomeres to either ICM or TE is due to
them undertaking different patterns of symmetric versus asym-
metric divisions from the 8-cell stage onwards (Bischoff et al.,
2008). Thus, it appears that although the development of mam-
malian embryos is highly regulative, cell fate decisions do not
occur at random, but that there is a developmental bias which can
be exposed under appropriate conditions. It may be possible to
magnify such bias (and thereby make it more amenable to study)
by expressing certain factors in a given blastomere. Hans Schöler
and colleagues showed that a reduction of the caudal type homeo
box 2 (Cdx2) gene product in the mouse blastocyst by RNA
interference alters cell fate and affects ES cell derivability (Wu
and Schöler, unpublished data). This finding revives the concept
originally explored in the so-called ‘altered nuclear transfer’ (ANT;
Hurlbut, 2005) approach, namely the possibility of using donor
nuclei mutated for one or more genes that are essential for
implantation in utero. Practically, a genetic mutation (ANT) or the
transcriptional manipulation of Cdx2 (‘knock down’ of its mRNA)
would pose a roadblock to placenta formation, thereby hindering
the possibility of cloning the animal while still allowing ES cell
derivation. This embryo would be ‘locked’ into a pluripotent but not
totipotent state, assuming once again that ES cells are pluripotent
but not totipotent. In this way, some of the ethical concerns related
to the generation of human ES cells might be relieved, although
the wisdom of preferring these embryos over the thousands
discarded every year from IVF programs should be pondered.
Cell fate flexibility in response to genetic and environmental
cues may not be an exclusive prerogative of early embryonic
cells. A property termed ‘plasticity’ has been controversially
attributed to adult stem cells (a central topic in the next section),
in relation to their ability to generate cell types of unrelated organs
(Wagers et al., 2004; Prockop, 2003). Unlike ES cells, adult stem
cells do exist in vivo in most but not all body organs and tissues.
Some think that during development, as potency becomes gradu-
ally restricted, somatic stem cells arise as remnants of more
potent cells that remain trapped and dormant in adult tissues. For
instance, one might hypothesize that adult stem cells arose from
primordial germ cells that migrated aberrantly to tissues outside
the gonads during development. Others think that adult stem cells
arise de novo in the tissue by other mechanisms, for instance by
cell fusion. Compared with ES cells, tissue-specific stem cells
have less self-renewal ability and, although they can differentiate
into multiple lineages, they are considered multipotent and not
pluripotent. Manipulation of adult stem cells’ plasticity would have
enormous potentials for regenerative medicine. Indeed, because
stem cells can be derived in larger numbers and relatively easily
from certain tissues (the best example probably being the he-
matopoietic compartment), the possibility of manipulating their
fate in a patient-customized manner would provide a basis for
syngeneic (homologous) tissue regeneration. However, it is diffi-
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cult to study plasticity when the ‘plastic’ cells are rare and hard to
identify (this is even more true in the blood where the identity of
the ‘true’ hematopoietic stem cells is still a matter of conjecture).
Studying histone lysine demethylation, Giuseppe Testa addressed
ways to make plasticity more amenable to study. Using mouse
macrophages challenged with pro-inflammatory cytokines, Natoli
and Testa addressed the role of histone lysine demethylation in
cell fate transitions. In particular they showed that the histone 3
lysine 27 (H3K27) de-methylase Jmjd3 promotes extensive epi-
genetic rearrangements resulting in cell identity changes in the
inflammatory response (De Santa et al., 2007). Studying a differ-
ent biological problem, namely the neural commitment of mouse
ES cells, Testa and colleagues found that Jmjd3 enables this
process by regulating key drivers and markers of neurogenesis,
indicating that H3K27 demethylation is apparently a common
mechanism involved in cell fate transitions (Testa, unpublished
data). It will be very interesting to test this response in other cell
types. In a different model system, Catherine Verfaillie and co-
workers have gathered evidence that cells derived from bone
marrow under specific culture conditions to isolate Multipotent
Adult Progenitor Cells (MAPCs) express a number but definitely
not all transcription factors known to endow ESC with pluripo-
tency. Like ES cells, some of the MAPC lines can participate in
normal development after injection in the blastocyst cavity of
mice, but unlike ES cells they have the advantage of not giving rise
to teratomas in vivo (Jiang et al., 2002a,b). A molecular portrait of
MAPCs is currently being pursued. Certain signalling cascades,
such as the TGFβ, Wnt and Notch pathways, are responsible for
controlling the plasticity of the MAPCs. At the transcriptome level,
MAPCs differ from classical mesenchymal stem cells (Ulloa-
Montoya et al., 2007). Whether MAPCs truly exist in the living
organism or whether they are artifacts due to reprogramming in
response to the very specific culture conditions used to isolate
them, is not known yet. However, this question may be regarded
as secondary to the actual benefits arising from the applications
of MAPCs.
Adult and cancer stem cells
The increasing interest of the public and scientific community
towards stem cells originates from their promise to regenerate
tissues or organs damaged by traumatic agents, impaired by
auto-immune processes or genetic disease, or ablated by inva-
sive oncological/surgical procedures. Currently, the best ex-
ample of therapeutic deployment of adult stem cells is certainly
the use of hematopoietic stem cells for bone marrow transplanta-
tion. In the past few years, several groups including that of
Maurilio Sampaolesi have reported a successful use of other
types of adult stem cells for the therapy of certain diseases, such
as myocardial necrosis and muscular dystrophy. Bone marrow-
derived stem cells and mesoangioblasts are incorporated into
regenerating skeletal muscle fibers when transplanted into dys-
trophic mice (Pelacho et al., 2007; Cossu and Sampaolesi, 2007;
Torrente et al., 2007) and dogs (Sampaolesi et al., 2006).
The recent identification of different types of multi-potent stem
cells, some of which are suitable for protocols of clinical cell
therapy, has disclosed new perspectives in the treatment of
genetic diseases, including muscular dystrophy. Sampaolesi
showed that a recently identified population of stem cells – the
mesoangioblasts (Tonlorenzi et al., 2007) – can confer functional
improvement upon intra-arterial injection in a mouse model of
muscular dystrophy (Sampaolesi et al., 2003). In particular, the
delivery of mesoangioblasts ameliorates function in vivo and
determines a recovery of force of contraction of skinned dystro-
phic muscle fibres in vitro. Moreover, by detecting dystrophin in
the same individual fibres used for force determination, it was
possible to show that muscle fibres which recover dystrophin
expression also recover force, whereas muscle fibres which do
not recover dystrophin expression do not recover force. The latter
finding has established the clearest link so far between the
recovery of expression of a missing protein and functional recov-
ery in dystrophic animals. More recently, transplantation of wild
-type canine mesoangioblasts gave promising results in the
Golden Retriever dystrophic dog (Sampaolesi et al., 2006, 2007),
the most reliable animal model that shows a form of muscular
dystrophy very similar to and even more severe lesions than
Duchenne muscular dystrophy. After the mouse and dog,
mesoangioblasts have been identified in humans and shown to
reconstitute dystrophin-expressing fibers in mdx/SCID mice
(Dellavalle et al., 2007). Based on these results, Dellavalle and
colleagues proposed a pilot clinical trial based on intra-arterial
transplantation of normal mesoangioblasts under a regime of
immune suppression. Efficacy and possible adverse effects are
up for evaluation to assess whether this approach may represent
a first step towards an efficacious cell therapy for muscular
dystrophy (Cossu and Sampaolesi, 2007).
Although stem cells could be a valuable therapeutic tool, they
may also be the target of certain pathogenic insults. Perhaps the
best proof of this concept has come over the past 5-10 years from
the identification of cancer-initiating cells dubbed ‘cancer stem
cells’ (CSC). Since the times of Virchow (“omnia cellula e cellula”
that is, all cells come from other cells), the cancer research
community has been looking for the cellular origin of human
cancers, but it is only now that a possible answer is taking shape.
Knowing which cells in a tumour-mass give rise to it and sustain
its growth is clearly fundamental, since only the eradication of
those cells can result in complete remission. In line with recent
reports from other groups (reviewed in Dirks, 2006), Ruggero De
Maria and colleagues have demonstrated that a very small
subpopulation of human CD133+ (a.k.a. prominin in mice) cells
within colorectal adenocarcinomas and all the major forms of lung
tumours behave as cancer-initiating cells (Ricci-Vitiani et al.,
2007; Eramo et al., 2008). These cells proliferate in culture in an
undifferentiated state, sustain tumour growth after xeno-trans-
plantation into NOD/SCID mice, and give rise in mice to cancers
phenotypically indistinguishable from the original human tumours.
Interestingly, De Maria showed that cancer-initiating cells in
glioblastoma, colorectal and lung tumours are much more resis-
tant than their more differentiated progeny to the conventional
chemotherapeutic drugs currently used in the clinical setting
(Eramo et al., 2006; Eramo et al., 2008; De Maria, unpublished
observations). The chemoresistance of the tumorigenic cell popu-
lations may explain why in many instances cancers progress
during therapy or relapse afterwards, and emphasizes the need
of CSC-targeted drugs for the cure of human cancers. The
mechanisms responsible for such chemoresistance remain to be
elucidated. Normal and cancer stem cells often express ABC
transporters that confer drug efflux capacity, easily measured by
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the flow-cytometric detection of the so-called ‘side population’ in
assays evaluating the efflux of fluorescent dyes such as Hoechst
33342. However, De Maria demonstrated that, at least in the case
of glioblastoma, CSCs can be resistant to chemotherapeutic
drugs regardless of the activity of ABC transporters (Eramo et al.,
2006). It is likely that the comparative characterization of the
survival pathways active in normal and cancer stem cells will be
a considerable contribution to devise novel and effective cancer
therapies.
Conclusions and perspectives
Stem cells represent probably the most rapidly evolving field of
research, bridging biology and medicine and reaching out to
society. This research topic has also raised harsh philosophical,
religious and political disputes. Until just a few years ago, cloning
was praised as a source for ES cells under the ‘therapeutic
cloning paradigm’. Now we hardly hear of it, although this method
is far from dead (Cibelli, 2007). On the one hand, animal cloning
raises deep concerns that one day we may be able to clone people
(however, we ought to keep in mind that cloning, after all, is only
one of many reproductive technologies that have been developed
in the past few decades, and all of them - artificial insemination,
embryo transfer, IVF - were unsafe and condemned at first but are
now much safer and are a big business). On the other hand, stem
cells are depicted by media as the ‘holy grail’ for the therapy of
certain incurable diseases, such as diabetes or neurodegenerative
disorders. Thus, it is important to assess where we actually stand
and how the stem cell field is likely to evolve.
Human ESCs are probably the best example of a tool endowed
with potential therapeutic benefit, nevertheless raising intricate
ethical issues. hESCs are in principle able to generate all the
tissues found in the adult body, but not to sustain TE formation,
unlike the zygote does. If ES cells were named totipotent, then
their status could be equated with that of the zygote, leading to
restriction or prohibition of their use in several countries. For this
reason, hESC have so far been considered pluripotent, thereby
escaping regulations aimed to protect the totipotent zygote. In
fact, hESCs can form trophectoderm-like cells spontaneously or
by exposure to BMP4 (Thomson et al., 1998; Gerami-Naini et al.,
2004; Xu et al., 2002) and the mouse ICM precursor of ES cells
can regenerate trophectoderm (Pierce et al., 1988). The recent
finding that mouse epiblast stem cells (Brons et al., 2007; Tesar
et al., 2007) are closer than mouse ES cells to hESCs as
measured by the gene expression profile, argues that hESCs
might, in fact, be a later stage than previously thought. If so,
whether human ES cells are pluri- or totipotent remains to be
determined, and the possibility that hESCs are totipotent may not
be ruled out. After all, not even the totipotent zygote is actually
totipotent on its own, as it needs a genital tract for recipient.
Likewise, ES cells need an embryo for recipient.
The source of hESC is another delicate issue, since their
generation requires the deployment of human embryos. Currently
iPS cells are the most attractive and popular surrogate of hESC,
while their generation does not require the consumption of em-
bryos. The iPS cells resemble ES cells in many aspects and have
been proposed to be pluripotent. However, one should be wary
that such a property is a function of in vitro culture conditions
(which still need to be optimized for iPS). Another pitfall associ-
ated with iPS is that so far they have only been generated by
retroviral transduction of selected genes. Even if the proto-
oncogene c-Myc is dispensable (Yu et al., 2007), such a proce-
dure cannot be considered safe in light of potential clinical
applications, since retroviral-mediated genome integration of the
transduced cDNAs can cause insertional mutagenesis and im-
pair, for instance, some onco-suppressor genes. Therefore, alter-
native means to convert adult somatic cells into iPS without the
risk of mutagenesis need to be implemented. Transient transfec-
tion of selected cDNAs or micro-injection of certain recombinant
proteins could be used to achieve somatic nuclei reprogramming.
By contrast, the news that proteins could be introduced via carbon
nanotubes into cells and turn them into iPS cells was received with
skepticism (Cyranoski and Baker, 2008). Inter-species nuclear
transfer would be another possibility. As discussed at this meet-
ing, such a procedure would spare human oocytes and embryos
while delivering pluripotent, HLA-matched ES cells usable for
regenerative medicine. At present, however, inter-species nuclear
transfer is a research tool and, because it involves human donor
nuclei, it is still very ethically controversial and banned in most
countries.
If pluripotency has to be imposed on somatic cells by artificial
means, we should first have a clear knowledge of the rules by
which pluripotency is established and maintained during physi-
ological development. Namely, what are the molecular mecha-
nisms that govern toti- and pluripotency in mammalian cells, and
is there any potential application of such mechanisms to the
purposes of regenerative medicine? Answers to these compelling
questions may come, not surprisingly, from the pre-eminent
biomedical model system: the mouse. For example, Magdalena
Zernicka-Goetz showed that certain epigenetic marks, such as
histone H3 methylation at Arginine 26 (H3R26Met), can have
profound effects on the fate of single blastomeres in mouse
embryos (Torres-Padilla et al., 2007). This may not be an exclu-
sive prerogative of early embryonic cells; for instance, the H3K27
histone de-methylase Jmjd3 was shown in this meeting to enable/
evoke identity changes in mouse macrophages (De Santa et al.,
2007) and differentiating ES cells. Thus, once we gain a detailed
picture of the epigenetic landscape of toti- and pluripotent cells,
we may be able to impose pluripotency on adult somatic nuclei in
a more efficient and safer way than we are currently doing (while
producing iPS cells, for instance).
The last issue addressed at this meeting was the emerging role
of stem cells as the target of certain pathogenic insults. CSCs or
cancer-initiating cells are probably the best example of stem cell-
like entities essential for the maintenance of a given lesion. The
existence of CSCs has been proven in hematopoietic neoplasms
(Lapidot et al., 1994; Bonnet and Dick, 1997) and in certain solid
tumours, including glioblastoma (Singh et al., 2003), breast ad-
enocarcinomas (Al Hajj et al., 2003), head-and-neck squamous
carcinomas (Prince et al., 2007), and colon (Ricci-Vitiani et al.,
2007), lung (Eramo et al., 2008) and pancreatic adenocarcino-
mas (Li et al., 2007). Cancer-initiating cells are predicted to be a
common theme to most, if not all, solid neoplasms and their
identification and characterization is probably only a matter of
short time. In line with this prediction, during this symposium we
learned that CSCs also appear to exist in thyroid cancers (De
Maria, unpublished observations).
CSCs usually represent a tiny fraction of the overall tumour
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burden, but are the only subpopulation capable of recapitulating
the phenotypic features of the tumour from which they are derived
when serially transplanted into NOD/SCID mice. CSCs have been
found to express several markers of stemness, such as the
surface antigen CD133, while the expression of pluripotency
transcription factors in CSCs still remains as questionable as it
has always been (Cantz et al., 2008). Therefore, the true potency
of CSCs remains unclear. A major question is whether CSCs are
derived from rare, adult somatic stem cells hit by oncogenic
insults or whether they are instead the product of an aberrant de-
differentiation of somatic progenitors. In the case of glioblastoma,
De Maria has shown that about 60% of the patients bear tumours
formed by multipotent CSCs able to generate both neural and
mesenchymal cells. Interestingly, this observation came from the
analysis of subcutaneous glioma stem cell xenografts, which in
some instances (25% of the patients) gave rise to mixed tumors
comprising areas of chondrocytic and osteocytic tissue (Ricci-
Vitiani et al., 2008). These new data are in line with previous
findings on melanoma stem cells, which have shown plasticity
towards multiple lineages (Fang et al., 2005). Although it is
theoretically possible that such multipotency is acquired following
a genetic reprogramming of a more differentiated cell during the
tumorigenic process, the multipotent frequency in glioma and
melanoma stem cells suggest that the tumorigenic hit may occur
in a normal stem cell. Whatever the answer, it is clear that if the
growth of human cancers is supported by a small population of
cancer-initiating cells, then any therapy should aim at killing this
population in order to be curative. Unfortunately, this conclusion
is a double-edged sword, because, as highlighted during this
meeting, CSCs tend to be more resistant to conventional chemo-
therapeutic agents and to radiation, as compared to their normal
counterparts (De Maria, unpublished data). Therefore, we envis-
age that two main routes should be followed in developing novel
anti-cancer therapeutics: CSC-specific targets need to be discov-
ered and, in parallel, knowledge has to be gained on the mecha-
nisms exploited by CSCs to resist anti-neoplastic drugs. Only in
this way it is likely that more selective and effective therapies will
become available and hopefully cure malignancies so far doomed
for a poor prognosis.
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